Colgate-Palmolive Company has declared a quarterly cash dividend of $0.53 per common share, payable on August 14, 2026, to shareholders of record on July 20, 2026. The company has paid uninterrupted dividends on its common stock since 1895, highlighting its long-standing commitment to returning value to shareholders.

Dividend Details

The Board of Directors approved the dividend, maintaining the company's consistent payout history. The upcoming payment continues a tradition of regular distributions that spans over a century.

Company Overview

Colgate-Palmolive Company operates as a consumer products organization focused on Oral Care, Personal Care, Home Care, and Pet Nutrition. The company sells its products in more than 200 countries and territories under brands such as Colgate, Palmolive, Hill's Science Diet, and Tom's of Maine. The firm is recognized for its sustainability initiatives, including efforts to reduce plastic waste and improve children's oral health through its Colgate Bright Smiles, Bright Futures program.

JPMorgan has maintained its Neutral rating on Colgate-Palmolive (India), setting a target price of ₹2,250. The brokerage's assessment reflects a broadly constructive view of the company's near-term prospects, anchored by a positive outlook for FY27 across multiple operational and demand-side parameters.

Key Rating Details

The following table summarises the core details of JPMorgan's rating on Colgate-Palmolive (India):

Growth Drivers and Demand Trends

JPMorgan's positive FY27 outlook is driven by a combination of volume and price growth, which the brokerage characterises as balanced. On the demand side, the assessment highlights improving urban demand alongside stable rural demand, suggesting a broad-based recovery in consumption trends. The brokerage also notes resilient category trends as a supporting factor for the company's performance trajectory.

Price hikes are described as manageable, indicating that any cost pass-through to consumers is not expected to materially disrupt volume momentum. This balance between pricing actions and volume sustenance forms a key pillar of the constructive FY27 view.

Premiumisation in Oral Care

A notable theme in JPMorgan's assessment is the ongoing premiumisation within Colgate-Palmolive India's oral care portfolio. The brokerage specifically identifies the following product lines as central to this strategy:

• Total — positioned as a premium oral health offering
• Whitening — catering to the growing consumer preference for aesthetic dental care
• PerioGard — targeting the therapeutic and specialised oral care segment

This premiumisation drive is seen as a structural growth lever, enabling the company to improve revenue mix and support margin outcomes over time.

Margin Outlook

Despite the expectation of higher brand investments, JPMorgan characterises the margin trajectory as stable to improving. This suggests that operational efficiencies and favourable pricing dynamics are anticipated to offset incremental spending on brand-building activities, supporting overall profitability.

Summary

JPMorgan's Neutral stance on Colgate-Palmolive (India) with a target price of ₹2,250 reflects a measured but positive view of the company's FY27 prospects. Balanced volume-price growth, premiumisation across oral care categories including Total, Whitening, and PerioGard, along with improving urban demand and stable rural demand, are cited as key positives. Margins are expected to remain stable to improving even as brand investment levels rise.